UPDATE 1-Aduro IPO pricing values drugmaker at $1 bln

April 14 (Reuters) - Aduro Biotech Inc's initial public offering has been priced at $17 per share, an underwriter said, valuing the cancer immunotherapy drug developer at about $1 billion.